Advertisement
Screener

Standard BioTools Inc. (LAB) Material Contracts, 2019

Standard BioTools Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2019-11-22: Form 8-K; Exhibit 10.2; Description Second Amendment to Loan and Security Agreement, dated November 20, 2019, between the Company and Silicon Valley Bank..
  • 2019-11-22: Form 8-K; Exhibit 10.1; Description Purchase Agreement, dated November 20, 2019, between Fluidigm Corporation and Barclays Capital Inc., as representative of the several initial purchasers named in Schedule I thereto..
  • 2019-11-08: Form 10-Q; Exhibit 10.1; Description Tenth Amendment to Lease Agreement between ARE-San Francisco No. 17, LLC and Fluidigm Corporation, dated August 14, 2019..
  • 2019-06-05: Form 8-K; Exhibit 10.1; Description Amended and Restated 2011 Equity Incentive Plan..
FiledFormExhibitDescription
2019-11-228-K10.2Second Amendment to Loan and Security Agreement, dated November 20, 2019, between the Company and Silicon Valley Bank.
2019-11-228-K10.1Purchase Agreement, dated November 20, 2019, between Fluidigm Corporation and Barclays Capital Inc., as representative of the several initial purchasers named in Schedule I thereto.
2019-11-0810-Q10.1Tenth Amendment to Lease Agreement between ARE-San Francisco No. 17, LLC and Fluidigm Corporation, dated August 14, 2019.
2019-06-058-K10.1Amended and Restated 2011 Equity Incentive Plan.
2019-05-0710-Q10.2First Amendment to Lease between AP3-SF3 CT North, LLC and Fluidigm Corporation, dated April 26, 2019.
2019-05-0710-Q10.1Lease between AP3-SF3 CT North, LLC and Fluidigm Corporation, dated March 20, 2019.
2019-03-1810-K10.18Offer Letter to Bradley A. Kreger dated February 13, 2018.

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01